The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
C12H22O11 + H2O → 2 C6H12O6 Heterolactic fermentation is in a sense intermediate between lactic acid fermentation and other types, e.g. alcoholic fermentation. Reasons to go further and convert lactic acid into something else include:
== Synonyms == In the 19th and the early 20th centuries, several synonyms were in use for erythritol: erythrol, erythrite, erythroglucin, eryglucin, erythromannite and phycite. Zerose is a tradename for erythritol.
== History == The structure of TRH was first determined, and the hormone synthesized, by Roger Guillemin and Andrew V. Schally in 1969. Both parties insisted their labs determined the sequence first: Schally first suggested the possibility in 1966, but abandoned it after Guillemin proposed TRH was not actually a peptide. Guillemin's chemist began concurring with these results in 1969, as NIH threatened to cut off funding for the project, leading both parties to return to work on synthesis. Schally and Guillemin shared the 1977 Nobel Prize in Medicine "for their discoveries concerning the peptide hormone production of the brain." News accounts of their work often focused on their "fierce competition" and use of a very large number of sheep and pig brains to locate the hormone.
The Federal Bureau of Narcotics (FBN) was established as an agency of the US Department of the Treasury by an act of June 14, 1930, with Harry J. Anslinger replacing Levi G. Nutt (who left under scandal) to be appointed as commissioner, a position he held for 32 years, until 1962. Anslinger supported Prohibition and the criminalization of all drugs, and spearheaded anti-drug policy campaigns. He did not support a public health and treatment approach, instead urging courts to "jail offenders, then throw away the key." He has been characterized as the first architect of the punitive war on drugs. According to a report prepared for the Senate of Canada, Anslinger was "utterly devoted to prohibition and the control of drug supplies at the source" and is "widely recognized as having had one of the more powerful impacts on the development of US drug policy, and, by extension, international drug control into the early 1970s." During his three decades heading the FBN, Anslinger zealously and effectively pursued harsh drug penalties, with a particular focus on cannabis. He used his stature as the head of a federal agency to draft legislation, discredit critics, discount medical opinion and scientific findings, and convince lawmakers. Publicly, he used the media and speaking engagements to introduce hyperbolic messages about the evils of drug use. In the 1930s, he referred to a collection of news reports of horrific crimes, making unsubstantiated claims attributing them to drugs, particularly cannabis.
== Statistical methods == The data generated in metabolomics usually consist of measurements performed on subjects under various conditions. These measurements may be digitized spectra, or a list of metabolite features. In its simplest form, this generates a matrix with rows corresponding to subjects and columns corresponding with metabolite features (or vice versa). Several statistical programs are currently available for analysis of both NMR and mass spectrometry data. A great number of free software are already available for the analysis of metabolomics data shown in the table. Some statistical tools listed in the table were designed for NMR data analyses were also useful for MS data. For mass spectrometry data, software is available that identifies molecules that vary in subject groups on the basis of mass-over-charge value and sometimes retention time depending on the experimental design. Once metabolite data matrix is determined, unsupervised data reduction techniques (e.g. PCA) can be used to elucidate patterns and connections. In many studies, including those evaluating drug-toxicity and some disease models, the metabolites of interest are not known a priori. This makes unsupervised methods, those with no prior assumptions of class membership, a popular first choice. The most common of these methods includes principal component analysis (PCA) which can efficiently reduce the dimensions of a dataset to a few which explain the greatest variation.
Sources: en.wikipedia.org
=== Discontinuation === The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time. There is tentative evidence that discontinuation of antipsychotics can result in psychosis. It may also result in reoccurrence of the condition that is being treated. Rarely tardive dyskinesia can occur when the medication is stopped.
The first large-scale application of strontium was in the production of sugar from sugar beet. Although a crystallisation process using strontium hydroxide was patented by Augustin-Pierre Dubrunfaut in 1849 the large scale introduction came with the improvement of the process in the early 1870s. The German sugar industry used the process well into the 20th century. Before World War I the beet sugar industry used 100,000 to 150,000 tons of strontium hydroxide for this process per year. The strontium hydroxide was recycled in the process, but the demand to substitute losses during production was high enough to create a significant demand initiating mining of strontianite in the Münsterland. The mining of strontianite in Germany ended when mining of the celestine deposits in Gloucestershire started. These mines supplied most of the world strontium supply from 1884 to 1941. Although the celestine deposits in the Granada basin were known for some time the large scale mining did not start before the 1950s. During atmospheric nuclear weapons testing, it was observed that strontium-90 is one of the nuclear fission products with a relatively high yield. The similarity to calcium and the chance that the strontium-90 might become enriched in bones made research on the metabolism of strontium an important topic.
=== Chronic urticaria === Chronic urticaria (CU) is characterized by wheal and flare symptoms of the skin lasting more than six weeks at a time. Symptoms of CU appear to be caused by the degranulation of mast cells in skin. CU has two subtypes: chronic inducible urticaria (CIndU, identifiable triggers) and chronic spontaneous urticaria (CSU, unpredictable triggers). In type I CSU, IgE autoantibodies are directed against self-antigens. In type IIb CSU, autoantibodies are directed against IgE or FcεRI.
With the help of Charles Stearn, an expert on vacuum pumps, in 1878, Swan developed a method of processing that avoided the early bulb blackening. This received a British Patent in 1880. On 18 December 1878, a lamp using a slender carbon rod was demonstrated at a meeting of the Newcastle Chemical Society though it only worked for a few minutes. Swan repeated the demonstration at another meeting on 17 January 1879 where it worked successfully. It was shown to 700 who attended a meeting of the Literary and Philosophical Society of Newcastle upon Tyne on 3 February 1879. The society's building was the first public building to be lit by electricity. The lamps Swan demonstrated used a carbon rod from an arc lamp rather than a slender filament. Thus they had low resistance and required very large conductors to supply the necessary current, so they were not commercially practical, although they furnished a demonstration of the possibilities of incandescent lighting with relatively high vacuum, a carbon conductor, and platinum lead-in wires. This bulb lasted about 40 hours. Swan then turned his attention to producing a better carbon filament and the means of attaching its ends. He devised a method of treating cotton to produce 'parchmentised thread' in the early 1880s and obtained British Patent 4933 that same year. From this year he began installing light bulbs in homes and landmarks in England. His house, Underhill, Low Fell, Gateshead, was the first in the world to be lit by a lightbulb. In the early 1880s he had started his company.
Materials science is an interdisciplinary field concerned with understanding the relationships between the structure of materials and their properties and using this knowledge to design materials for specific applications. The internal structure of a material—from atomic arrangements to microscopic features—strongly influences its mechanical, electrical, thermal, and optical behavior. In engineering practice, materials science and engineering are often described through the processing–structure–properties–performance paradigm, in which processing determines structure, structure determines properties, and properties ultimately control the performance of a material in service. The intellectual origins of materials science stem from the Age of Enlightenment, when researchers began to use analytical thinking from chemistry, physics, and engineering to understand ancient, phenomenological observations in metallurgy and mineralogy. Materials science still incorporates elements of physics, chemistry, and engineering. As such, the field was long considered by academic institutions as a sub-field of these related fields. Beginning in the 1940s, materials science began to be more widely recognized as a specific and distinct field of science and engineering, and major technical universities around the world created dedicated schools for its study. By studying how the history of a material (processing) influences its structure, properties, and performance, materials scientists have made many contributions to new technologies in biomaterials, metallurgy, and nanotechnology.
Sources: en.wikipedia.org
== Efficacy == Hydrocolloid has been shown to be superior to other dressing substrates (e.g., alginate, film, gauze, hydrofiber, or silicone) tested for treating skin-graft donor sites. There is tentative but unclear (as of 2013) evidence for the efficacy of hydrocolloid dressings for superficial and partial-thickness burns. The results of meta-analyses indicate no significant difference in healing rates between hydrocolloid dressings and other dressings (including simple gauze dressings) for venous ulcers, or for diabetic foot ulcers.
Because ovulation is triggered by a surge in estradiol levels at mid-cycle, estrogen exposure during elagolix therapy might be greater around this time in some women. In addition to its activity as a GnRH antagonist, elagolix is a weak to moderate inducer of CYP3A and an inhibitor of P-glycoprotein. As a result, elagolix may affect the metabolism and/or transport of other medications, and this may contribute to drug interactions with elagolix.
12 July – Members of the NASUWT teaching union in England vote to stage strike action over pay, with 85.5% of members voting to do so on a 51.9% turnout. 13 July – Data released by NHS England indicates that 7.47 million people were waiting to begin routing hospital treatment in June 2023, an increase from 7.42 million in May. The UK government proposes a 6.5% pay rise for teachers, with the leaders of all four major teaching unions expressing support for the increase, meaning strikes by teachers in England are likely to end. Pradjeet Veadhasa, 17, and Sukhman Shergill, 17, are sentenced to life imprisonment with minimum terms of 18 and 16 years respectively for the June 2022 murder of 16-year-old Ronan Kanda in Wolverhampton, who they stabbed after mistaking him for an enemy. 14 July – The UK Health Security Agency warns that tens of thousands of cases of measles could potentially occur in London because of low vaccination numbers there. A 65-year-old man is charged with the murders of Naomi Hunte, who was stabbed to death in February 2022, and Fiona Holm, who disappeared in June 2023 and whose body has not been found. The UK government approves plans to build a road tunnel near Stonehenge. Following trial and conviction at Portsmouth Crown Court, Sarah Somerton-How and her lover, George Webb, are both sentenced to 11 years imprisonment for wilful neglect and holding a person in slavery or servitude after they kept Somerton-How's husband, who has cerebral palsy and is severely sight impaired, a prisoner in squalid conditions for four years.
1967: Sue Arnold became the first female British Geological Survey person to go to sea on a research vessel. 1967: South African radiobiologist Tikvah Alper discovered that scrapie, an infectious brain disease affecting sheep, did not spread via DNA or RNA like a viral or bacterial disease. The discovery enabled scientists to better understand diseases caused by prions. 1967: Yvonne Brill, a Canadian-American rocket and jet propulsion engineer, invented the hydrazine resistojet propulsion system. 1968: Japanese pioneer of molecular biology Tsuneko Okazaki studied DNA replication and discovered Okazaki fragments. 1969: British biostratigrapher Beris Cox became the first female paleontologist in the British Geological Survey. 1969: British botanist Irene Manton became the first woman president of the British Pteridological Society. 1969: Ukrainian-born astronomer Svetlana Gerasimenko co-discovered the 67P/Churyumov–Gerasimenko comet. 1969: A group of women scientists from the United States (Lois Jones, Terry Tickhill, Kay Lindsay, Eileen McSaveney, and Jean Pearson) and New Zealand (Pamela Young) become the first women to visit and work at the South Pole.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.